Stryker Co. (NYSE:SYK) Stock Holdings Increased by Everence Capital Management Inc.

Everence Capital Management Inc. boosted its stake in shares of Stryker Co. (NYSE:SYK) by 47.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,880 shares of the medical technology company’s stock after purchasing an additional 2,550 shares during the period. Everence Capital Management Inc.’s holdings in Stryker were worth $2,847,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Cooper Financial Group boosted its position in Stryker by 10.2% during the first quarter. Cooper Financial Group now owns 905 shares of the medical technology company’s stock valued at $324,000 after purchasing an additional 84 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Stryker in the 1st quarter valued at approximately $143,000. Strategic Planning Group LLC increased its holdings in Stryker by 17.2% in the first quarter. Strategic Planning Group LLC now owns 3,986 shares of the medical technology company’s stock worth $1,426,000 after buying an additional 584 shares during the last quarter. Annex Advisory Services LLC raised its position in Stryker by 17.7% during the first quarter. Annex Advisory Services LLC now owns 1,878 shares of the medical technology company’s stock valued at $672,000 after acquiring an additional 283 shares in the last quarter. Finally, Riverview Trust Co bought a new stake in Stryker in the first quarter worth approximately $175,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

SYK stock traded down $0.25 during trading on Monday, reaching $369.31. 373,837 shares of the stock were exchanged, compared to its average volume of 1,249,121. The stock has a 50 day simple moving average of $355.79 and a 200-day simple moving average of $343.20. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $140.69 billion, a P/E ratio of 42.19, a price-to-earnings-growth ratio of 2.85 and a beta of 0.91. Stryker Co. has a twelve month low of $255.22 and a twelve month high of $374.63.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period in the previous year, the business posted $2.54 earnings per share. Stryker’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s payout ratio is presently 36.53%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $386.00 price target on shares of Stryker in a report on Wednesday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $380.00 price target on shares of Stryker in a research report on Tuesday, September 10th. UBS Group upped their price target on Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus decreased their target price on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $381.16.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at approximately $949,716. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 220,068 shares of company stock worth $71,811,372 in the last 90 days. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.